Recurrence of venous thromboembolism associated with rivaroxaban use compared to enoxaparin in cancer patients
No Thumbnail Available
Sponsors
Date
Journal Title
Format
Poster
Subject
Abstract
BACKGROUND: In the treatment of venous thromboembolism(VTE) in cancer patients, two trials that have shown superiority of the use of a low-molecular-weight heparin (LMWH) as compared to standard therapy of initial treatment with a LMWH followed by a vitamin K antagonist (VKA). Novel oral anticoagulants including rivaroxabanhave not been compared to LMWH in treatment of VTE in cancer patients. The EINSTEIN DVT and EINSTEIN PE trials included only 6 percent and 4.6 percent of patients with cancer, respectively, and thus more evidence is necessary to support the use of rivaroxabanin cancer patients.
Table of Contents
DOI
PubMed ID
Degree
Thesis Department
Rights
All rights reserved to the author(s) of the poster.